Affinia Therapeutics

Waltham, MA · Founded 2019 · Privately Held (backing)

Developer of an adeno-associated virus gene therapy platform intended to focus on diseases affecting the central nervous system and muscles. Affinia Therapeutics is based in Waltham, MA and was founded in 2019. It was valued at $145 million at its later-stage round in Oct 2025, the last priced event on record. It has raised $210 million across 3 recorded rounds; the latest was a $13.3 million early-stage round in Sep 2025.

PMV mark · valuation
$145.0M
Oct 2026
Priced at
its later-stage round
Oct 2025
Total raised
$210.0M
Last round
Early Stage VC
Sep 2025

Who backs Affinia Therapeutics?

19 investors
InvestorType
RA Capital ManagementAsset manager
GVVenture capital
Service Provider CapitalVenture capital
New Enterprise AssociatesVenture capital
F-Prime CapitalVenture capital
Eight RoadsAsset manager
Alexandria Venture InvestmentsOther
Casdin CapitalVenture capital
Perceptive AdvisorsHedge fund
Atlas VentureOther
+ 9 more investors · a free account shows the complete list
The directory is free. Investor activity — the working column — is Pro.Unlock prospecting columns

Membership and data by Private Market View

Affinia Therapeutics investors

19 investors are on record for Affinia Therapeutics, including RA Capital Management, GV, Service Provider Capital and New Enterprise Associates. By type, the record holds 5 venture capital firms, 5 hedge funds and 3 asset managers. The early-stage round in Sep 2025 drew 20 investors.

Free account
More of Affinia Therapeutics with a free account
  • ·The complete investor list: 19 names
  • ·Watch Affinia Therapeutics: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

For fundraisers
Work this list, don’t just read it

These 19 firms already write checks for companies like Affinia Therapeutics. Build the wider list: every firm that has backed a company like this one, ranked by how often and how recently.

Find investors like these →

Membership and data by Private Market View